Crizotinib, which targets both Anaplastic Lymphoma Kinase (ALK) and MET, has been reported with a remarkable response in a woman with ALK-rearranged ATC [52], and entered an ongoing phase II study for the treatment of solid tumors including MET-mutated thyroid cancers (https://clinicaltrials.gov/ct2/show/NCT02034981). This evidence concerns the gene MET and thyroid gland carcinoma.